Clinical Trial: A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07189949) titled 'A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications' on Sept. 17.

Brief Summary: This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Intervention: DRUG: HRS-2329 Tablet

Oral HRS-2329 tablet.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Publish...